drugset

drugset / Trial / NCT07286656

A Study of GensSci098 in Subjects With Graves' Disease

NCT07286656 ↗

Phase 1 Recruiting 24 enrolled Changchun GeneScience Pharmaceutical Co., Ltd.

NaSequentialOpen-labelTreatment

Summary

To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease

Timeline

Start: 2025-11-21
Primary completion: 2026-10-28
Completion: 2027-03-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GenSci098	Unknown	—	Subcutaneous

Indications